Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

August 6, 2025 UCBN News, Syndication Comments Off on Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., Aug. 6, 2025 /PRNewswire/ — Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on July…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

No Picture
News

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

July 20, 2022 UCBN News Comments Off on Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine (Hematology and […]